News

Video

Evaluating Pirtobrutinib in Patients with R/R Mantle Cell Lymphoma

Author(s):

Kami J. Maddocks, MD,Alexey V. Danilov, MD, PhD

Experts discuss data on pirtobrutinib, a non-covalent BTK inhibitor, in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Related Videos
Leo I. Gordon, MD
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
BTK Inhibitors in Late-Relapse Mantle Cell Lymphoma | Image Credit: © Dr_Microbe - stock.adobe.com
November 19th 2024

Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma

Lori A. Leslie, MD
February 27th 2023

FDA Approval Insights: Pirtobrutinib in MCL

Michael Wang, MD
November 5th 2024

Indirect Comparison Shows Comparable Efficacy, Improved Safety for Acalabrutinib vs Ibrutinib in R/R Mantle Cell Lymphomal Lymphoma

Joshua Brody, MD
December 8th 2022

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

Michael Wang, MD
October 22nd 2024

Acalabrutinib Plus Venetoclax/Rituximab Yields 100% ORR in Treatment-Naive Mantle Cell Lymphoma

CAR T-Cell Therapy in R/R Mantle Cell Lymphoma | Image Credit: © Dr_Microbe - stock.adobe.com
October 14th 2024

Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma